Market Research Report
Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023
|Published by||Allied Market Research||Product code||563322|
|Published||Content info||150 Pages
Delivery time: 2-3 business days
|Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023|
|Published: September 1, 2017||Content info: 150 Pages||
Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period. The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.
The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Type of Drug
The key players operating in this market include